Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer

被引：41
作者：
Barrio, Martin [1 ]
Fendler, Wolfgang P. [1 ,2 ]
Czernin, Johannes [1 ]
Herrmann, Ken [1 ,3 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
[2] Ludwig Maximilians Univ Munchen, Dept Nucl Med, Munich, Germany
[3] Univ Hosp Essen, Dept Nucl Med, Essen, Germany
来源：
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2016年 / 16卷 / 11期
关键词：
PET; PSMA; Gallium; Lutetium; prostate cancer; therapy; theranostic; POSITRON-EMISSION-TOMOGRAPHY; RADIOLIGAND THERAPY; C-11-CHOLINE PET/CT; BIOCHEMICAL RELAPSE; RADIATION-DOSIMETRY; RADICAL PROSTATECTOMY; BONE-SCINTIGRAPHY; RADIONUCLIDE THERAPY; RECURRENCE; BIODISTRIBUTION;
D O I：
10.1080/14737159.2016.1243057
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Introduction: Prostate specific membrane antigen (PSMA) has become an attractive diagnostic and therapeutic target for small molecule ligands. Radionuclide-chelating ligands can be labeled with either Ga-68 for positron-emission-tomography (PET) or Lu-177 for radionuclide therapy.Areas covered: In this literature review we evaluate the diagnostic value of Ga-68 PSMA PET/CT and the therapeutic potential of Lu-177 PSMA radioligand therapy (RLT) in patients with prostate cancer. Ga-68 PSMA PET/CT is more accurate than CT for nodal staging and superior to conventional imaging in patients with biochemical recurrence, translating into major changes in clinical management. The preliminary data for Lu-177 PSMA indicates >50% reduction of PSA levels in up to 59% of patients. Severe adverse events occurred <10% of patients after RLT.Expert commentary: PSMA ligands for diagnostic and therapeutic purpose will significantly impact the management of patients with prostate cancer.
引用
收藏
页码：1177 / 1188
页数：12
相关论文
共 102 条
[11]   THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience [J].
Baum, Richard P. ;
Kulkarni, Harshad R. .
THERANOSTICS, 2012, 2 (05) :437-447
[12]  
Beckett ML, 1999, CLIN CANCER RES, V5, P4034
[13]   Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies [J].
Ben Jemaa, Awatef ;
Bouraoui, Yosra ;
Sallami, Sataa ;
Banasr, Ahmed ;
Ben Rais, Nawfel ;
Ouertani, Latifa ;
Nouira, Yassin ;
Horchani, Ali ;
Oueslati, Ridha .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2010, 29
[14]   Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer [J].
Benesova, Martina ;
Schaefer, Martin ;
Bauder-Wuest, Ulrike ;
Afshar-Oromieh, Ali ;
Kratochwil, Clemens ;
Mier, Walter ;
Haberkorn, Uwe ;
Kopka, Klaus ;
Eder, Matthias .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) :914-920
[15]   A Systematic Review of the Role of Imaging before Salvage Radiotherapy for Post-prostatectomy Biochemical Recurrence [J].
Beresford, M. J. ;
Gillatt, D. ;
Benson, R. J. ;
Ajithkumar, T. .
CLINICAL ONCOLOGY, 2010, 22 (01) :46-55
[16]   68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT [J].
Bluemel, Christina ;
Krebs, Markus ;
Polat, Buelent ;
Linke, Fraenze ;
Eiber, Matthias ;
Samnick, Samuel ;
Lapa, Constantin ;
Lassmann, Michael ;
Riedmiller, Hubertus ;
Czernin, Johannes ;
Rubello, Domenico ;
Bley, Thorsten ;
Kropf, Saskia ;
Wester, Hans-Juergen ;
Buck, Andreas K. ;
Herrmann, Ken .
CLINICAL NUCLEAR MEDICINE, 2016, 41 (07) :515-521
[17]  
Boschi S, 2016, EUR J NUCL IN PRESS
[18]  
Bostwick DG, 1998, CANCER-AM CANCER SOC, V82, P2256, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO
[19]  
2-S
[20]   Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study [J].
Bratan, Flavie ;
Niaf, Emilie ;
Melodelima, Christelle ;
Chesnais, Anne Laure ;
Souchon, Remi ;
Mege-Lechevallier, Florence ;
Colombel, Marc ;
Rouviere, Olivier .
EUROPEAN RADIOLOGY, 2013, 23 (07) :2019-2029
12345678910